SBP-101 (Ivospemin)
Other Solid Tumors
ResearchPipeline
Key Facts
About Panbela Therapeutics
Panbela Therapeutics is a clinical-stage biotech focused on developing novel polyamine analog therapeutics for oncology, with a lead program in pancreatic cancer. The company's core achievement is advancing ivospemin (SBP-101) into a global Phase 3 trial (ASPIRE) for metastatic pancreatic ductal adenocarcinoma, following promising Phase 1b data. Its strategy centers on a capital-efficient, virtual model, targeting high-mortality cancers where polyamine pathway dysregulation is a key driver. Panbela aims to establish a new treatment paradigm by disrupting a fundamental metabolic pathway common across many aggressive tumors.
View full company profileTherapeutic Areas
Other Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Vigil Platform | Gradalis | Research/Pre-clinical |
| Ivonescimab (AK112) | Akeso | Phase III |
| VDC Platform | Aura Biosciences | Discovery |
| Mitazalimab | Alligator Bioscience AB | Phase 1/2 |